Compare Johnson & Johnson (JNJ) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Unity Software Inc — how do they compare? Johnson & Johnson trades at $256.44 (market cap $622.84B), while Unity Software Inc trades at $46.1 (market cap $20.00B). The key difference: Johnson & Johnson is far larger — about 31.1× Unity Software Inc's market cap, and Johnson & Johnson pays a 2.07% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Unity Software Inc for 50 Days on average.
| JNJ | U | |
|---|---|---|
Market Cap | $622.84B | $20.00B |
Volume | 5,277,426 | 12,798,386 |
Sector | Health | Technology |
52-Week High | $278.43 | $49.47 |
52-Week Low | $186.00 | $17.13 |
Typical Hold Time | 129 Days | 50 Days |
Enterprise Value | $651.12B | $19.88B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, up 0.67% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net income margin and 25.74% ROE, though valuation metrics appear elevated with P/E of 29.98. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales and Q3 earnings anticipation.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and elevated valuation. Analyst consensus targets $286.53 (11.7% upside) with 52.5% buy ratings. Key risks include biosimilar competition for Stelara and debt-to-asset ratio increase to 24.06% in 2025.
Unity Software (U) trades at $45.89, up 2.09% today, with strong technical momentum and bullish analyst sentiment. The stock shows improving fundamentals with revenue stabilizing around $1.8B-$2.0B and narrowing losses, though profitability remains negative. Recent catalysts include Meta VR Glasses support and positive sector momentum from Accenture's earnings. Technical indicators show the stock trading near resistance at $46 with overbought short-term RSI conditions.
Outlook remains cautiously optimistic with 82% analyst buy ratings and $45.27 consensus target. Key opportunities include VR/AR growth and advertising platform expansion, while risks center on persistent losses, high valuation multiples, and competitive pressures. The stock's current level near analyst targets suggests limited near-term upside without significant earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
